Scientific overview of myasthenia gravis and an assessment of the role of plasmapheresis.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000818:Animals; D001323:Autoantibodies / Q000032:analysis; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000628:therapy; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D051379:Mice; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000145:classification / Q000276:immunology* / Q000628:therapy; D010641:Phenotype; D010956:Plasmapheresis / Q000009:adverse effects; D011247:Pregnancy; D011817:Rabbits; D011950:Receptors, Cholinergic / Q000032:analysis / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D013934:Thymectomy; D013950:Thymus Gland / Q000166:cytology / Q000276:immunology
D000305:Adrenal Cortex Hormones; D001323:Autoantibodies; D002800:Cholinesterase Inhibitors; D007166:Immunosuppressive Agents; D011950:Receptors, Cholinergic